A 1960s blueprint became tomorrow’s tech

During a time when medical devices were heavy, analog, and tethered to a wall, a soft-spoken tinkerer imagined something radically different. The engineer, Earl Bakken, sketched out a 100-year vision that was so fantastical it could have been ripped from a science-fiction pulp magazine.

Bakken was fascinated with the idea of using electricity to improve quality of life and his vision included radical ideas like using electricity to treat incontinence and pain.

Bakken, who built a medical device company out of a garage in Minnesota, mapped out a blueprint for the future of healthcare technology in the early 1960s that charted in surprising accuracy the innovations that now help millions of patients live healthier, longer lives. Many of his ideas, like “bladder stimulators,” “radio pills,” and implantable pacemakers, are in hospitals and physicians’ offices around the world today.

From basic to state of the art 

The Medtronic pacemakers below represent important leaps in engineering that revolutionized the patient experience. 

His foresight is what makes Bakken the “Nostradamus” of healthcare technology, said Bill Peine, the vice president of surgical research and technology at Medtronic, the company Bakken co-founded and led for 40 years.

“It’s inspiring that our leader, decades ago, had these visions, had this capability to see where we should be going,” he said.

Bakken’s vision remains a touchstone inside Medtronic labs, guiding decisions and the future of healthcare technology six decades later. But there are corners of today’s medical world — advances even Bakken couldn’t foresee — that push the blueprint into new territory.

From sci-fi to standard of care

Through his plan, Bakken tried to bring order to the unknown, sketching a systematic vision of a future that didn’t yet exist.

“It was a roadmap of biomedical engineering,” said Jason Case, vice president of research and development in the Acute Care & Monitoring business at Medtronic. “He had, on one axis, categories of technology, and on another axis, invasiveness to the human body. And he mapped solutions across it.”

The framework guided the company’s early research and development, Case said. It set Medtronic on the path from its first breakthrough — the battery-powered pacemaker — and later, laid the groundwork for therapies that now address more than 70 health conditions.

It also seeded a long-running thread inside the company: a commitment to making therapies smaller, smarter, and more integrated with the body itself — an evolution from external devices toward solutions that seem almost invisible to the patient.

Bakken’s early thinking around bladder stimulators became today’s InterStim™ therapy for types of urinary and fecal incontinence¹; his concept of a miniaturized pacemaker evolved into a device that is implantable fully within the heart like the Micra™² leadless pacemaker, which doesn’t require a chest incision nor does it leave a bump under the skin. Even his pill-sized diagnostics idea now exists in the form of PillCam™³ capsule endoscopy that helps doctors see inside the body.

“The 100-year plan gave people permission to dream, but it also said where Medtronic would engage and what areas we should leave for somebody else to do,” said Kim Chaffin, vice president of enterprise technologies at Medtronic and a friend of Bakken’s. Before his death in 2018, Bakken gifted Chaffin a framed copy of the plan. It hangs on the wall across from her desk.

“There was a very clean delineation on what was in the heart of the Medtronic future,” she said of Bakken’s vision. “And I think we still do that today.”

But even a blueprint this clear can leave space for mystery. There are pieces of Bakken’s plan that leave even today’s brightest engineering minds puzzled over what he meant when he wrote things like “electric sleep.”

“We can hypothesize what he was thinking, but that’s for our future scientists and engineers to decode,” Chaffin said.

The blueprint and beyond

Understanding how to restore the heart’s electrical rhythm helped Medtronic apply those same insights to other parts of the body — such as using neuromodulation to help guide electrical signals in the brain and nervous system. Take the Percept™ family of devices,⁴ a closed-loop brain sensing system that allows clinicians to adapt stimulation to reduce tremors, slowness, and stiffness for patients with movement disorders.

“If we didn’t understand how the heart worked, and how the electrical conduction systems worked, we could never anticipate arrhythmias and correct them,” she said. “And by being able now to sense in the brain, this is unlocking a whole new part of the body where we can start to anticipate, and sense, and innovate based upon that signal.”

Bakken’s grid for the future was organized by categories and invasiveness, a framework brilliantly suited for devices, less so for intelligent learning systems.

“I think one aspect that wasn’t on Earl Bakken’s vision is artificial intelligence,” Peine said. “I don’t think he saw that coming. And that has completely shifted the landscape of our daily lives.”

Innovations like advanced imaging, robotics, wearables, and artificial intelligence are propelling Bakken’s blueprint into the future.

“All of these are frontiers where our company will explore and expand and really deliver therapy in a completely new way that’s going to impact patients significantly,” Peine said. “It’s going to change everything.”

One of those advancements, which Peine is close to, is Hugo™, a robotic-assisted surgery system⁵ that builds on decades of groundbreaking innovations that made minimally invasive soft-tissue surgery possible and globally scalable. Robotic-assisted surgery systems enable surgeons to perform minimally invasive surgery with great precision, operating through few, small incisions, meaning less scarring and quicker recovery time.^6-8 The Hugo™ RAS system amplifies a surgeon’s hands, eyes, and brain through small, dexterous instruments, 3D visualization, and the computational power of AI, Peine said.

Yet the Hugo™ RAS system represents just one thread in a much larger story, one now guided by leaders focused on what will define the next era of healthcare.

For Nathalie Virag, who leads the Bakken Research Center in the Netherlands, an international research center that drives end-to-end product innovation, Earl Bakken’s 100-year blueprint was less about predicting the future than about navigating it. 

His vision still guides how Medtronic decides where to focus innovation, shaping a disciplined process in which thousands of ideas are explored, tested, and refined by a global technical community. Only a few become products, but that deliberate prioritization is how Bakken’s vision endures.

Virag met Bakken as a new Medtronic employee in 1998. He was “a dreamer,” she recalled. In a landscape that is brimming with possibilities, Bakken’s vision helps center the company around what’s both possible and best for patients, she said. 

“Artificial intelligence is impacting all eras of our society,” Virag said. “And healthcare will be no exception.”

Ignoring transformative technologies like AI carries real risk at a time when patient needs are growing faster than the healthcare workforce. True to Earl Bakken’s focus on unmet needs, Medtronic sees innovation not as optional or novel, but as the only scalable way to extend care, improve experiences, and help more people live longer, healthier lives.

Bakken gave Medtronic a map when the future felt unknown. Today’s teams are expanding his vision in directions he never could have plotted — guided by new tools, new sciences, and new ways of understanding the body. The blueprint remains, but it is no longer a destination. It’s a launching point.

Published March 20, 2026